vs
安波福（APTV）与梯瓦制药（TEVA）财务数据对比。点击上方公司名可切换其他公司
安波福的季度营收约是梯瓦制药的1.1倍（$5.2B vs $4.7B），梯瓦制药净利率更高（10.2% vs 2.7%，领先7.5%），梯瓦制药同比增速更快（11.4% vs 5.0%），梯瓦制药自由现金流更多（$1.0B vs $651.0M），过去两年梯瓦制药的营收复合增速更高（11.1% vs 2.5%）
安波福（Aptiv）是源自美国的全球知名汽车技术供应商，总部设于瑞士沙夫豪森。其前身是通用汽车旗下的零部件业务板块，后独立为德尔福汽车系统，经业务拆分重组后正式成立安波福，服务全球各大整车制造企业。
梯瓦制药工业有限公司是以色列跨国制药企业，核心业务聚焦仿制药研发生产，同时布局品牌药、药用活性成分（API）业务，也小范围开展合同生产服务及对外授权合作相关业务。
APTV vs TEVA — 直观对比
营收规模更大
APTV
是对方的1.1倍
$4.7B
营收增速更快
TEVA
高出6.4%
5.0%
净利率更高
TEVA
高出7.5%
2.7%
自由现金流更多
TEVA
多$365.0M
$651.0M
两年增速更快
TEVA
近两年复合增速
2.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.2B | $4.7B |
| 净利润 | $138.0M | $481.0M |
| 毛利率 | 18.7% | 56.4% |
| 营业利润率 | 8.2% | 6.4% |
| 净利率 | 2.7% | 10.2% |
| 营收同比 | 5.0% | 11.4% |
| 净利润同比 | -48.5% | 321.7% |
| 每股收益（稀释后） | $0.63 | $0.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APTVTEVA
| Q4 25 | $5.2B | $4.7B | ||
| Q3 25 | $5.2B | $4.5B | ||
| Q2 25 | $5.2B | $4.2B | ||
| Q1 25 | $4.8B | $3.9B | ||
| Q4 24 | $4.9B | $4.2B | ||
| Q3 24 | $4.9B | $4.3B | ||
| Q2 24 | $5.1B | $4.2B | ||
| Q1 24 | $4.9B | $3.8B |
净利润APTVTEVA
| Q4 25 | $138.0M | $481.0M | ||
| Q3 25 | $-355.0M | $433.0M | ||
| Q2 25 | $393.0M | $282.0M | ||
| Q1 25 | $-11.0M | $214.0M | ||
| Q4 24 | $268.0M | $-217.0M | ||
| Q3 24 | $363.0M | $-437.0M | ||
| Q2 24 | $938.0M | $-846.0M | ||
| Q1 24 | $218.0M | $-139.0M |
毛利率APTVTEVA
| Q4 25 | 18.7% | 56.4% | ||
| Q3 25 | 19.5% | 51.4% | ||
| Q2 25 | 19.1% | 50.3% | ||
| Q1 25 | 19.1% | 48.2% | ||
| Q4 24 | 19.6% | 50.2% | ||
| Q3 24 | 18.6% | 49.6% | ||
| Q2 24 | 19.2% | 48.6% | ||
| Q1 24 | 17.9% | 46.4% |
营业利润率APTVTEVA
| Q4 25 | 8.2% | 6.4% | ||
| Q3 25 | -3.4% | 19.7% | ||
| Q2 25 | 9.3% | 10.9% | ||
| Q1 25 | 9.3% | 13.3% | ||
| Q4 24 | 9.8% | -0.7% | ||
| Q3 24 | 10.4% | -1.2% | ||
| Q2 24 | 8.7% | -0.1% | ||
| Q1 24 | 8.5% | -5.7% |
净利率APTVTEVA
| Q4 25 | 2.7% | 10.2% | ||
| Q3 25 | -6.8% | 9.7% | ||
| Q2 25 | 7.5% | 6.8% | ||
| Q1 25 | -0.2% | 5.5% | ||
| Q4 24 | 5.5% | -5.1% | ||
| Q3 24 | 7.5% | -10.1% | ||
| Q2 24 | 18.6% | -20.3% | ||
| Q1 24 | 4.4% | -3.6% |
每股收益（稀释后）APTVTEVA
| Q4 25 | $0.63 | $0.42 | ||
| Q3 25 | $-1.63 | $0.37 | ||
| Q2 25 | $1.80 | $0.24 | ||
| Q1 25 | $-0.05 | $0.18 | ||
| Q4 24 | $1.22 | $-0.19 | ||
| Q3 24 | $1.48 | $-0.39 | ||
| Q2 24 | $3.47 | $-0.75 | ||
| Q1 24 | $0.79 | $-0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.9B | $3.6B |
| 总债务越低越好 | $7.5B | — |
| 股东权益账面价值 | $9.2B | $7.9B |
| 总资产 | $23.4B | $40.7B |
| 负债/权益比越低杠杆越低 | 0.81× | — |
8季度趋势，按日历期对齐
现金及短期投资APTVTEVA
| Q4 25 | $1.9B | $3.6B | ||
| Q3 25 | $1.6B | $2.2B | ||
| Q2 25 | $1.4B | $2.2B | ||
| Q1 25 | $1.1B | $1.7B | ||
| Q4 24 | $1.6B | $3.3B | ||
| Q3 24 | $1.8B | $3.3B | ||
| Q2 24 | $2.2B | $2.3B | ||
| Q1 24 | $941.0M | $3.0B |
总债务APTVTEVA
| Q4 25 | $7.5B | — | ||
| Q3 25 | $7.6B | — | ||
| Q2 25 | $7.8B | — | ||
| Q1 25 | $7.6B | — | ||
| Q4 24 | $7.8B | — | ||
| Q3 24 | $8.3B | — | ||
| Q2 24 | $5.5B | — | ||
| Q1 24 | $4.7B | — |
股东权益APTVTEVA
| Q4 25 | $9.2B | $7.9B | ||
| Q3 25 | $9.3B | $7.3B | ||
| Q2 25 | $9.7B | $6.8B | ||
| Q1 25 | $9.0B | $6.3B | ||
| Q4 24 | $8.8B | $5.4B | ||
| Q3 24 | $8.9B | $6.1B | ||
| Q2 24 | $11.5B | $6.4B | ||
| Q1 24 | $11.1B | $7.3B |
总资产APTVTEVA
| Q4 25 | $23.4B | $40.7B | ||
| Q3 25 | $23.5B | $39.9B | ||
| Q2 25 | $23.9B | $40.1B | ||
| Q1 25 | $23.1B | $38.4B | ||
| Q4 24 | $23.5B | $39.3B | ||
| Q3 24 | $24.8B | $41.8B | ||
| Q2 24 | $24.8B | $41.3B | ||
| Q1 24 | $23.6B | $42.8B |
负债/权益比APTVTEVA
| Q4 25 | 0.81× | — | ||
| Q3 25 | 0.82× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.85× | — | ||
| Q4 24 | 0.89× | — | ||
| Q3 24 | 0.93× | — | ||
| Q2 24 | 0.48× | — | ||
| Q1 24 | 0.42× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $818.0M | $1.2B |
| 自由现金流经营现金流 - 资本支出 | $651.0M | $1.0B |
| 自由现金流率自由现金流/营收 | 12.6% | 21.6% |
| 资本支出强度资本支出/营收 | 3.2% | 3.0% |
| 现金转化率经营现金流/净利润 | 5.93× | 2.41× |
| 过去12个月自由现金流最近4个季度 | $1.5B | $1.1B |
8季度趋势，按日历期对齐
经营现金流APTVTEVA
| Q4 25 | $818.0M | $1.2B | ||
| Q3 25 | $584.0M | $369.0M | ||
| Q2 25 | $510.0M | $227.0M | ||
| Q1 25 | $273.0M | $-105.0M | ||
| Q4 24 | $1.1B | $575.0M | ||
| Q3 24 | $499.0M | $693.0M | ||
| Q2 24 | $643.0M | $103.0M | ||
| Q1 24 | $244.0M | $-124.0M |
自由现金流APTVTEVA
| Q4 25 | $651.0M | $1.0B | ||
| Q3 25 | $441.0M | $233.0M | ||
| Q2 25 | $361.0M | $131.0M | ||
| Q1 25 | $76.0M | $-232.0M | ||
| Q4 24 | $894.0M | $446.0M | ||
| Q3 24 | $326.0M | $545.0M | ||
| Q2 24 | $417.0M | $6.0M | ||
| Q1 24 | $-21.0M | $-248.0M |
自由现金流率APTVTEVA
| Q4 25 | 12.6% | 21.6% | ||
| Q3 25 | 8.5% | 5.2% | ||
| Q2 25 | 6.9% | 3.1% | ||
| Q1 25 | 1.6% | -6.0% | ||
| Q4 24 | 18.2% | 10.5% | ||
| Q3 24 | 6.7% | 12.6% | ||
| Q2 24 | 8.3% | 0.1% | ||
| Q1 24 | -0.4% | -6.5% |
资本支出强度APTVTEVA
| Q4 25 | 3.2% | 3.0% | ||
| Q3 25 | 2.7% | 3.0% | ||
| Q2 25 | 2.9% | 2.3% | ||
| Q1 25 | 4.1% | 3.3% | ||
| Q4 24 | 3.4% | 3.1% | ||
| Q3 24 | 3.6% | 3.4% | ||
| Q2 24 | 4.5% | 2.3% | ||
| Q1 24 | 5.4% | 3.2% |
现金转化率APTVTEVA
| Q4 25 | 5.93× | 2.41× | ||
| Q3 25 | — | 0.85× | ||
| Q2 25 | 1.30× | 0.80× | ||
| Q1 25 | — | -0.49× | ||
| Q4 24 | 3.96× | — | ||
| Q3 24 | 1.37× | — | ||
| Q2 24 | 0.69× | — | ||
| Q1 24 | 1.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APTV
| Electrical Distribution Systems | $2.3B | 45% |
| Engineered Components Group | $1.4B | 28% |
| Active Safety | $716.0M | 14% |
| User Experience And Other | $564.0M | 11% |
| Smart Vehicle Compute And Software | $154.0M | 3% |
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
